has developed a unique technology on the basis of clinical proteome analysis, enabling the early and differential detection of cardiovascular, renal, biliary and urogenital diseases. Furthermore, diagnostic tests for additional indications, such as Alzheimer's disease, pancreatic cancer and nephrotoxic effects of drugs are in development. Diagnosis is accomplished by highly specific patterns of multiple simultaneously detected biomarkers (proteins/polypeptides) from patient samples obtained in a risk-free and painless procedure. Mosaiques utilizes high resolution capillary electrophoresis coupled mass spectrometry (CE-MS technology), which enables the separation of body fluids in less than one hour. Proprietary software affords the analysis of huge amounts of data within minutes.